Enrichment Design : Additional Screening Process

Identification of a human subject into a study for a clinical trial involves screening and placebo run in periods. In some cases additional screening process is required as some therapeutic agents will be effective in patients with some disorders as they show changes in response. Hence, an additional screening process called Enrichment design is employed in the clinical trials which includes active treatments as it helps in easy identification of patients in whom test agents are found to be beneficial during early phase of trial. They also helps in identification of patients with better therapeutic response. Thus, this additional screening process restricts the target population into a very small selective group during the clinical trial making the trial process easier and effective.